drugset / Trial / NCT01259531
Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)
Phase 4
Completed
100 enrolled
JW Pharmaceutical
Asan Medical Center · collabChonbuk National University Hospital · collabChonnam National University Hospital · collabKangdong Sacred Heart Hospital · collabKorea University Guro Hospital · collabPusan National University Hospital · collabSamsung Medical Center · collabSeoul National University Hospital · collabSeoul St. Mary's Hospital · collabYeungnam University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This clinical study is designed to evaluate the efficacy and safety of silodosin in a 12 week treatment of patients with severe urinary disorders associated with benign prostatic hyperplasia (BPH).
Timeline
- Start
- 2010-12
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Silodosin | Unknown | 8 mg | — |